Biotech Startups

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions. The company serves patients, physicians, and healthcare systems across oncology, women's health, and organ health.

8 investors

Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees. The device targets phantom limb and residual limb pain, letting patients start therapy on demand.

8 investors

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

8 investors

OrganOx develops organ preservation and transplantation technology used by research institutions to keep and treat organs, aimed at supporting transplantation and reducing the future need for transplants. It operates in the medical device and organ technology sector.

8 investors

Recursion applies computational and data-driven approaches to biological science, aiming to accelerate drug discovery and develop new treatments. The company combines life scientists and software engineers to solve problems at the intersection of biology and technology.

8 investors

Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients. It operates in the digital health and biotech space, aiming to treat conditions through a combination of biology, behavior, and technology.

8 investors

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

8 investors

SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs. The company applies this "neuroimmune modulation" approach to autoimmune disease care.

8 investors

Sonavex develops medical device technologies focused on vascular access and related clinical applications, drawing on ultrasound-based imaging and monitoring products. The company serves clinical and surgical care settings, particularly in the dialysis and renal care space.

8 investors

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases. The company uses proprietary platform technologies to create targeted and durable Treg cell therapies.

8 investors

Umami Bioworks develops cultivated seafood production, focusing on endangered, threatened, or protected fish species using genomics, stem cell biology, and machine learning through its ALKEMYST platform. It offers a scalable, automated solution for seafood producers to make cultivated seafood.

8 investors

Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.

8 investors

ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields. Its biodegradable materials target industries including personal hygiene, fashion and apparel, and coatings, aiming to reduce reliance on fossil-based sources and microplastics.

8 investors

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis. The company is a clinical-stage biopharmaceutical firm running Phase 2/3 trials of its immunology treatments.

7 investors

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology. Its lead candidate, ADCX-020, is being evaluated in a Phase 1 study in patients with advanced solid tumors.

7 investors

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.

7 investors

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.

7 investors

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.

7 investors

Develops alternative textile materials to replace polyester and reduce the fashion industry's plastic consumption and carbon emissions.

7 investors

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.

7 investors

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.

7 investors

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer. The company focuses on cell therapy for cancer treatment.

7 investors

Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.

7 investors

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

7 investors